Copenhagen, Denmark; December 5, 2013 – Genmab A/S (OMX: GEN) will webcast its Post ASH investor seminar focused on the company’s latest developments in antibody innovation on December 10, 2013 from 7:30PM to 9:30PM CET. At the seminar key opinion leaders will discuss and put into perspective data from studies of ofatumumab and daratumumab presented at the 2013 Annual Meeting of the American Society of Hematology (ASH) and Genmab will provide information on progress with the company’s proprietary antibody technologies, and expected performance milestones for 2014.
Help employers find you! Check out all the jobs and post your resume.
